Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
David Goodman-MezaMatthew R BeymerRyan M KofronK Rivet AmicoChristina PsarosLane R BushmanPeter L AndersonRobert BolanWilbert C JordanJames F RooneyAmy R WohlRaphael J LandovitzPublished in: AIDS care (2019)
PrEP's potential benefit for men who have sex with men (MSM) who use stimulants may be limited by adherence or prescriber willingness to recommend PrEP due to concerns of non-compliance. Using data from PATH-PrEP, a 48-week study evaluating PrEP for MSM in Los Angeles, we modeled an interaction between stimulant use and condomless sex with multiple partners (CAS-MP) on prevention-effective dried blood spot tenofovir-diphosphate concentrations. At week 4, participants reporting stimulant use and CAS-MP had a decreased odds of prevention-effective adherence compared to non-stimulant use and non-CAS-MP (AOR 0.15, 95% CI 0.04-0.57). From week 4-48, participants reporting stimulant use and CAS-MP had increased odds of prevention-effective adherence (AOR 1.06 per week, 95%CI 1.01-1.12). Participants reporting CAS-MP without stimulant use had no significant change in prevention-effective adherence (AOR 0.99 per week, 95%CI 0.96-1.02). Stimulant use moderated the association of CAS-MP on prevention-effective PrEP adherence over time.
Keyphrases
- men who have sex with men
- hiv testing
- attention deficit hyperactivity disorder
- hiv positive
- crispr cas
- genome editing
- autism spectrum disorder
- adverse drug
- risk assessment
- type diabetes
- glycemic control
- working memory
- placebo controlled
- randomized controlled trial
- emergency department
- machine learning
- human immunodeficiency virus
- antiretroviral therapy
- study protocol
- hiv infected
- hepatitis c virus